Wave Life Sciences Ltd.

For the period ended Mar 31, 2026. Filed Apr 28, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed Apr 28, 2026

WVE$3.41-2.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Unaudited Consolidated Balance Sheets

(In thousands, except share amounts)

	March 31, 2026	December 31, 2025
Assets
Current assets:
Cash and cash equivalents	$544,591	$602,068
Accounts receivable	—	1,276
Prepaid expenses	13,225	8,395
Other current assets	3,456	3,075
Total current assets	561,272	614,814
Long-term assets:
Property and equipment, net of accumulated depreciation of $50,352 and $49,522 as of March 31, 2026 and December 31, 2025, respectively	7,077	7,405
Operating lease right-of-use assets	10,994	12,458
Restricted cash	3,815	3,806
Other assets	386	16
Total long-term assets	22,272	23,685
Total assets	$583,544	$638,499
Liabilities, Series A preferred shares, and shareholders’ equity
Current liabilities:
Accounts payable	$19,064	$15,700
Accrued expenses and other current liabilities	13,043	26,564
Current portion of deferred revenue	9,396	44,440
Current portion of operating lease liability	8,328	8,361
Total current liabilities	49,831	95,065
Long-term liabilities:
Deferred revenue, net of current portion	14,596	7,798
Operating lease liability, net of current portion	7,387	9,405
Total long-term liabilities	21,983	17,203
Total liabilities	$71,814	$112,268
Series A preferred shares, no par value; nil and 3,901,348 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively	$—	$7,874
Shareholders’ equity:
Ordinary shares, no par value; 192,337,566 and 187,660,263 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively	$1,626,879	$1,616,478
Additional paid-in capital	237,428	228,365
Accumulated other comprehensive loss	(254)	(250)
Accumulated deficit	(1,352,323)	(1,326,236)
Total shareholders’ equity	$511,730	$518,357
Total liabilities, Series A preferred shares, and shareholders’ equity	$583,544	$638,499

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.